"Modulation of Immunologic Responses to HIV-1(MN) Recombinant gp160 Vaccine by Dose and Schedule of Administration."

According to the authors' abstract of an article published in Vaccine, "The safety and immunogenicity of HIV-1(MN) recombinant gp160 (MN rgp160) vaccine in healthy, uninfected volunteers was tested in a double-blind study with a factorial design. By random assignment, 20 volunteers received three 200 (mu)g doses of MN rgp160 and four volunteers received placebo at days 0, 28, and 168 or 0, 56, and 224. Of the 24 volunteers, 16 received 200 (mu)g or 800 (mu)g of MN rgp160 and two received placebo at day 532 (month 18). The vaccine was safe. It induced T-cell memory measured by Th1 cytokine production and lymphocyte proliferation, and serum anti-MN rgp160 IgG (all subclasses) and IgA...

Want to see the full article?

• Purchase this article for only $3.00